Commense Bio, Inc.
Biopharmaceutical company developing genetically engineered bacterial therapeutics that occupy the skin microbiome to prevent colonization by disease-causing bacteria. The company applies a platform of genetically-modified live biotherapeutics that use bacterial interference and programmed self-destruction to address multiple invasive infectious-disease indications.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
CB-502
Lead investigational bacterial therapeutic program targeting S. aureus (MRSA/MSSA) with indications that include recurrent skin and soft tissue infection and surgical site infection; non-antibiotic approach intended to avoid antimicrobial resistance.
CB-212
Investigational program targeting recurrent urinary tract infections caused by E. coli using engineered bacterial therapeutics intended to prevent pathogenic colonization.
CB-105
Program targeting Pseudomonas aeruginosa infections in cystic fibrosis via engineered bacterial therapeutics intended to limit pathogenic colonization.
CB-321
Program focused on prevention or management of surgical infections (S. epidermidis) using engineered bacterial therapeutics.
CB-424
Program targeting Cutibacterium acnes (acne) using engineered bacteria to modulate skin microbiome composition.
CB-502
Lead investigational bacterial therapeutic program targeting S. aureus (MRSA/MSSA) with indications that include recurrent skin and soft tissue infection and surgical site infection; non-antibiotic approach intended to avoid antimicrobial resistance.
CB-212
Investigational program targeting recurrent urinary tract infections caused by E. coli using engineered bacterial therapeutics intended to prevent pathogenic colonization.
CB-105
Program targeting Pseudomonas aeruginosa infections in cystic fibrosis via engineered bacterial therapeutics intended to limit pathogenic colonization.
CB-321
Program focused on prevention or management of surgical infections (S. epidermidis) using engineered bacterial therapeutics.
CB-424
Program targeting Cutibacterium acnes (acne) using engineered bacteria to modulate skin microbiome composition.
Expertise Areas
- Bacterial therapeutics development
- Microbiome engineering and colonization strategies
- Genetic modification of bacterial strains
- Preclinical and IND-enabling studies
Key Technologies
- Genetically-modified live bacterial therapeutics
- Microbiome-based competitive exclusion
- Programmable bacterial kill-switches (self-destruction)
- Targeted decolonization and replace strategies
News & Updates
Site post referencing company technology and updates (listed as 'Coming soon').
Site post referencing company technology and updates (listed as 'Coming soon').